# Combination Immunotherapy in Rare Cancers Under InvesTigation

Source: https://onco.cc/trials/nct04969887/  
OnCo record `nct04969887` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 2 trial of nivolumab and ipilimumab in gallbladder cancer and other biliary tract cancers, run by Olivia Newton-John Cancer Research Institute, active and no longer recruiting.

## Summary

Combination Immunotherapy in Rare Cancers Under InvesTigation is a phase 2 interventional study registered as NCT04969887 by Olivia Newton-John Cancer Research Institute, with a registry enrolment figure of 240 participants, started 2021-08-03 and due to reach its primary completion in 2025-03-01. Interventions recorded: Ipilimumab, Nivolumab. Conditions listed: Advanced Biliary Tract Cancer, Neuroendocrine Tumors, Female Reproductive System Neoplasm, MSI-H Solid Malignant Tumor. Gallbladder cancer is named in the registry entry: "* a) Histologically confirmed Neuroendocrine cancers: Atypical bronchial carcinoid, neuroendocrine carcinoma and Grade 3 NETs independent of primary site (SCLC excluded); Biliary Tract Cancers: Intrahepatic cholangiocarc". Sites: Australia, New Zealand. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-24
- Also known as: MOST-CIRCUIT
- Tags: ctgov-ingest; gallbladder-deep-dive
- Registry id: NCT04969887
- Phase: 2
- Setting: Ipilimumab and Nivolumab Combination Therapy in Patients With Selected Immunotherapy Sensitive Advanced Rare Cancers
- Sponsor: Olivia Newton-John Cancer Research Institute
- Enrolled: 240

## Sources

- ClinicalTrials.gov NCT04969887: https://clinicaltrials.gov/study/NCT04969887

## Connected records

- cancers: [Biliary tract cancer (all types)](https://onco.cc/cancers/biliary-tract-cancer/), [Biliary tract cancer (cholangiocarcinoma)](https://onco.cc/cancers/cholangiocarcinoma/), [Gallbladder cancer](https://onco.cc/cancers/gallbladder/), [Intrahepatic cholangiocarcinoma](https://onco.cc/cancers/intrahepatic-cholangiocarcinoma/)
- technologies: [Immune checkpoint inhibitors](https://onco.cc/technologies/checkpoint-inhibitor/)
- drugs: [Ipilimumab](https://onco.cc/drugs/ipilimumab/), [Nivolumab](https://onco.cc/drugs/nivolumab/)
- key papers: [Nivolumab and Ipilimumab Combination Treatment in Advanced Ovarian and Endometrial Clear Cell Cancers: A Nonrandomized Clinical Trial](https://onco.cc/key-papers/paper-nct04969887-jama-oncol-2025/)
- terms: [Gallbladder cancer in biliary tract cancer trials (eligibility and subgroups)](https://onco.cc/terms/gallbladder-cancer-in-biliary-trials/)

---
JSON: https://onco.cc/api/v1/entities/nct04969887.json